Further preclinical studies of specific autophagy inhibitors, such as novel Vps34 inhibitors, or compounds and strategies that specifically mediate induction of cytotoxic autophagy in cancer cells, such as cannabinoids, will inform the design of early‐phase clinical trials and drive the efficacy of personalized targeted medicine that harnesses autophagy modulation of the benefit of patients with metastatic melanoma. This evidence concerns the gene PIK3C3 and metastatic melanoma.